{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:09:51Z","timestamp":1761862191420,"version":"3.40.4"},"reference-count":3,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron"],"published-print":{"date-parts":[[2002]]},"abstract":"<jats:p>Different types of vasculitis have been reported in association with hepatitis C virus (HCV) infection, i.e. type II mixed cryoglobulinemia and polyarteritis nodosa (PAN). Therapeutic approach of such severely symptomatic patients include interferon-alpha (IFN) plus plasma exchange (PE). There are no data on IFN pharmacokinetic changes related to PE. &lt;i&gt;Patients and Methods:&lt;\/i&gt; We studied 7 HCV-infected patients (mean age: 57 years) presenting with symptomatic type II mixed cryoglobulinemia (n = 5) or biopsy-proven PAN (n = 2). All patients underwent subcutaneous IFN therapy with concomitant PE. Serum IFN concentration was measured in serial samples on days with and without PE. &lt;i&gt;Results:&lt;\/i&gt; Without PE, IFN C&lt;sub&gt;max &lt;\/sub&gt;(range: 100\u2013750 IU\/ml) was obtained 3\u20136 h after subcutaneous injection, followed by a 3- to 9-hour plateau. IFN concentration declined subsequently reaching a residual concentration 24 h after injection, ranging from 20 to 40\u00a0IU\/ml. PE performed 6 h after IFN administration resulted in increased IFN clearance in that the concentration-time IFN-\u03b1 area under the curve decreased from 3,005 IU\u00b7h\/ml (1,563\u20134,614) on days without PE to 2,142 IU\u00b7h\/ml (973\u20134,123) on day with PE. &lt;i&gt;Conclusions:&lt;\/i&gt; In patients with HCV-associated vasculitis, PE increase IFN clearance. Combined IFN-\u03b1 and PE therapy schedule have to be further studied to optimize its biological activity.<\/jats:p>","DOI":"10.1159\/000065023","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:17Z","timestamp":1050440717000},"page":"627-630","source":"Crossref","is-referenced-by-count":22,"title":["Plasma Exchange and Interferon-Alpha Pharmacokinetics in Patients with Hepatitis C Virus-Associated Systemic Vasculitis"],"prefix":"10.1159","volume":"91","author":[{"given":"P.","family":"Hausfater","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Assogba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Piette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2002,7,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(88)90125-6"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000045125"}],"container-title":["Nephron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/65023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/65023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:25:39Z","timestamp":1745468739000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000065023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":3,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2002,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000065023","archive":["Portico"],"relation":{},"ISSN":["1660-8151","2235-3186"],"issn-type":[{"type":"print","value":"1660-8151"},{"type":"electronic","value":"2235-3186"}],"subject":[],"published":{"date-parts":[[2002]]}}}